Rockefeller Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$377 Hold
200
– – ﹤0.01% 4758
2026
Q2
$370 Hold
200
– – ﹤0.01% 4623
2026
Q1
$426 Hold
200
– – ﹤0.01% 4573
2025
Q4
$486 Hold
200
– – ﹤0.01% 4533
2025
Q3
$758 Buy
+200
New +$585 ﹤0.01% 4221

Other funds holding BDTX

Rockefeller Capital Management's BDTX Position: Q3 2026 in Review

Rockefeller Capital Management held its Black Diamond Therapeutics (BDTX) position steady in Q3 2026 at 200 shares worth $377. The position accounts for ﹤0.01% of the portfolio, ranked #4758.

Rockefeller Capital Management first reported a position in BDTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $758 in Q3 2025. 111 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.

  • Rockefeller Capital Management held 200 shares of Black Diamond Therapeutics worth $377 as of Q3 2026.
  • Rockefeller Capital Management left its Black Diamond Therapeutics share count unchanged in Q3 2026.
  • Black Diamond Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4758 holding.
  • Rockefeller Capital Management first reported a position in Black Diamond Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Rockefeller Capital Management's Black Diamond Therapeutics position peaked at $758 in Q3 2025.
  • 111 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.